FrancophonIA/ELRC3.0 huggingface dataset:
English: Temomedac 5 mg hard capsules have a white opaque body and cap with two stripes in green ink on the cap and with “T 5 mg” in green ink on the body.
Estonian: Temomedac 5 mg kõvakapslitel on läbipaistmatu valge põhiosa ja kaas, kaanel rohelise tindiga tehtud kaks triipu ning põhiosal rohelise tindiga märgistus „T 5 mg”.
English: INFORMATION IN BRAILLE Temomedac 20 mg
Estonian: Temomedac 20 mg
English: INFORMATION IN BRAILLE Temomedac 140 mg
Estonian: Temomedac 140 mg
English: Temomedac 5 mg hard capsules
Estonian: Temomedac 5 mg kõvakapslid
English: Temomedac is indicated for the treatment of: - adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.
Estonian: • täiskasvanud patsientidele esmaselt diagnoositud multiformse glioblastoomi raviks samaaegselt radioteraapiaga (RT) ning järgnevaks monoteraapiaks
English: Temomedac 140 mg hard capsules: Each capsule contains 140 mg temozolomide.
Estonian: Temomedac 1400 mg kõvakapslid: Iga kapsel sisaldab 140 mg temosolomiidi.
English: INFORMATION IN BRAILLE Temomedac 250 mg
Estonian: Temomedac 250 mg
English: Temomedac 250 mg hard capsules
Estonian: Temomedac 250 mg kõvakapslid
English: Temomedac 250 mg hard capsules have a white opaque body and cap with two stripes in black ink on the cap and with “T 250 mg” in black ink on the body.
Estonian: Temomedac 250 mg kõvakapslitel on läbipaistmatu valge põhiosa ja kaas, kaanel musta tindiga tehtud kaks triipu ning põhiosal musta tindiga märgistus „T 250 mg”.
English: Temomedac 140 mg hard capsules shellac, propylene glycol, indigo carmine (E132) aluminium lake
Estonian: Temomedac 140 mg kõvakapslid šellak propüleenglükool indigokarmiin Aluminium Lake (E 132)
English: Temomedac 140 mg two stripes in blue ink on the cap and “T 140 mg” in blue ink on the body
Estonian: Temomedac 140 mg kaanel sinise tindiga kaks triipu ning põhiosal sinise tindiga „T 140 mg”
English: Temomedac 100 mg hard capsules: Each capsule contains 100 mg temozolomide.
Estonian: Temomedac 100 mg kõvakapslid: Iga kapsel sisaldab 100 mg temosolomiidi.
English: INFORMATION IN BRAILLE Temomedac 100 mg
Estonian: Temomedac 100 mg
English: Table 4: Treatment-emergent events during concomitant and monotherapy treatment phases in patients with newly-diagnosed glioblastoma multiforme
Estonian: Samaaegse ravi ja monoteraapia ajal ilmnenud kõrvaltoimed esmaselt diagnoositud multiformse glioblastoomiga patsientidel
English: Temomedac 20 mg hard capsules
Estonian: Temomedac 20 mg kõvakapslid
English: Temomedac 20 mg hard capsules have a white opaque body and cap with two stripes in orange ink on the cap and with “T 20 mg” in orange ink on the body.
Estonian: Temomedac 20 mg kõvakapslitel on läbipaistmatu valge põhiosa ja kaas, kaanel oranži tindiga tehtud kaks triipu ning põhiosal oranži tindiga märgistus „T 20 mg”.
English: Temomedac 20 mg hard capsules shellac propylene glycol, titanium dioxide (E171) sunset yellow FCF (E110) aluminium lake
Estonian: Temomedac 20 mg kõvakapslid šellak propüleenglükool titaandioksiid (E 171) päikeseloojangukollane FCF Aluminium Lake (E 110)
English: Temomedac 100 mg two stripes in pink ink on the cap and “T 100 mg” in pink ink on the body
Estonian: Temomedac 100 mg kaanel roosa tindiga kaks triipu ning põhiosal roosa tindiga „T 100 mg”
English: Temomedac 140 mg hard capsules
Estonian: Temomedac 140 mg kõvakapslid
English: Temomedac 100 mg hard capsules: gelatin, titanium dioxide (E 171), red iron oxide (E 172), shellac, propylene glycol and yellow iron oxide (E 172).
Estonian: Temomedac 100 mg kõvakapslid: želatiin, titaandioksiid (E 171), punane raudoksiid (E 172), šellak, propüleenglükool ja kollane raudoksiid (E 172).
English: Temomedac 180 mg hard capsules
Estonian: Temomedac 180 mg kõvakapslid
English: Temomedac 140 mg hard capsules: gelatin, titanium dioxide (E 171), shellac, propylene glycol, indigo carmine (E 132) aluminium lake.
Estonian: Temomedac 140 mg kõvakapslid: želatiin, titaandioksiid (E 171), šellak, propüleenglükool, indigokarmiin Aluminium Lake (E 132).
English: Capsule content anhydrous lactose, sodium starch glycolate Type A, colloidal anhydrous silica, tartaric acid, stearic acid
Estonian: A-tüüpi naatriumtärklisglükolaat kolloidne veevaba ränidioksiid viinhape steariinhape
English: Temomedac 180 mg two stripes in red ink on the cap and “T 180 mg” in red ink on the body
Estonian: Temomedac 180 mg kaanel punase tindiga kaks triipu ning põhiosal punase tindiga „T 180 mg”
English: Skin and subcutaneous tissue disorders Very rare:
Estonian: Naha ja nahaaluskoe kahjustused Väga harv
English: The hard capsules (length approx. 16 mm) have a white opaque body and cap with two stripes in green ink on the cap and with “T 5 mg” in green ink on the body.
Estonian: Kõvakapslitel (pikkus ligikaudu 16 mm) on läbipaistmatu valge põhiosa ja kaas, kaanel rohelise tindiga tehtud kaks triipu ning põhiosal rohelise tindiga märgistus „T 5 mg”.
English: Temomedac 100 mg hard capsules
Estonian: Temomedac 100 mg kõvakapslid
English: The hard capsules (length approx. 18 mm) have a white opaque body and cap with two stripes in orange ink on the cap and with “T 20 mg” in orange ink on the body.
Estonian: Kõvakapslitel (pikkus ligikaudu 18 mm) on läbipaistmatu valge põhiosa ja kaas, kaanel oranži tindiga tehtud kaks triipu ning põhiosal oranži tindiga märgistus „T 20 mg”.
English: Temomedac 180 mg hard capsules have a white opaque body and cap with two stripes in red ink on the cap and with “T 180 mg” in red ink on the body.
Estonian: Temomedac 180 mg kõvakapslitel on läbipaistmatu valge põhiosa ja kaas, kaanel punase tindiga tehtud kaks triipu ning põhiosal punase tindiga märgistus „T 180 mg”.
English: Temomedac 140 mg hard capsules have a white opaque body and cap with two stripes in blue ink on the cap and with “T 140 mg” in blue ink on the body.
Estonian: Temomedac 140 mg kõvakapslitel on läbipaistmatu valge põhiosa ja kaas, kaanel sinise tindiga tehtud kaks triipu ning põhiosal sinise tindiga märgistus „T 140 mg”.
English: Adverse reactions in patients with recurrent or progressive malignant glioma Infections and infestations
Estonian: Taastuva või progresseeruva pahaloomulise glioomiga patisentidel esinenud kõrvaltoimed Üldised häired ja manustamiskoha reaktsioonid
English: Temomedac 100 mg hard capsules have a white opaque body and cap with two stripes in pink ink on the cap and with “T 100 mg” in pink ink on the body.
Estonian: Temomedac 100 mg kõvakapslitel on läbipaistmatu valge põhiosa ja kaas, kaanel roosa tindiga tehtud kaks triipu ning põhiosal roosa tindiga märgistus „T 100 mg”.
English: EU/1/09/605/012
Estonian: EU/1/09/605/011 EU/1/09/605/012
English: Your doctor will work out your dose of Temomedac.
Estonian: Teie rst määrab kindlaks Temomedaci õige annuse.
English: Temomedac 250 mg hard capsules: gelatin, titanium dioxide (E 171), shellac, propylene glycol, black iron oxide (E 172).
Estonian: Temomedac 250 mg kõvakapslid: želatiin, titaandioksiid (E 171), šellak, propüleenglükool, must raudoksiid (E 172).
English: The hard capsules (length approx. 22 mm) have a white opaque body and cap with two stripes in black ink on the cap and with “T 250 mg” in black ink on the body.
Estonian: Kõvakapslitel (pikkus ligikaudu 22 mm) on läbipaistmatu valge põhiosa ja kaas, kaanel musta tindiga tehtud kaks triipu ning põhiosal musta tindiga märgistus „T 250 mg”.
English: NAME OF THE MEDICINAL PRODUCT Temomedac 20 mg hard capsules temozolomide
Estonian: Temomedac 20 mg kõvakapslid temosolomiid
English: NAME OF THE MEDICINAL PRODUCT Temomedac 180 mg hard capsules temozolomide
Estonian: Temomedac 180 mg kõvakapslid temosolomiid
English: Respiratory, thoracic and mediastinal disorders Very rare:
Estonian: Respiratoorsed, rindkere ja mediastiinumi häired Väga harv
English: NAME OF THE MEDICINAL PRODUCT Temomedac 250 mg hard capsules temozolomide
Estonian: Temomedac 250 mg kõvakapslid temosolomiid
English: Blood and lymphatic system disorders Very rare:
Estonian: Vere ja lümfisüsteemi häired Väga harv
English: How to store Temomedac
Estonian: Kuidas Temomedaci säilitada
English: 20 hard capsules
Estonian: 5 kõvakapslit 20 kõvakapslit
English: The hard capsules (length approx. 22 mm) have a white opaque body and cap with two stripes in red ink on the cap and with “T 180 mg” in red ink on the body.
Estonian: Kõvakapslitel (pikkus ligikaudu 22 mm) on läbipaistmatu valge põhiosa ja kaas, kaanel punase tindiga tehtud kaks triipu ning põhiosal punase tindiga märgistus „T 180 mg”.
English: Temomedac 250 mg hard capsules shellac, black iron oxide (E172), propylene glycol
Estonian: Temomedac 250 mg kõvakapslid šellak must raudoksiid (E 172) propüleenglükool
English: The hard capsules (length approx. 20 mm) have a white opaque body and cap with two stripes in pink ink on the cap and with “T 100 mg” in pink ink on the body.
Estonian: Kõvakapslitel (pikkus ligikaudu 20 mm) on läbipaistmatu valge põhiosa ja kaas, kaanel rohelise tindiga tehtud kaks triipu ning põhiosal roosa tindiga märgistus „T 100 mg”.
English: Very common (may affect more than 1 in 10 people): loss of appetite, headache, constipation (difficulty passing stools), nausea (feeling sick in your stomach), vomiting, rash, hair loss, tiredness.
Estonian: Väga sage (võib tekkida rohkem kui ühel inimesel 10st): isukaotus, peavalu, kõhukinnisus
English: Pancytopenia, anaemia (Grade 3 - 4), leukopenia
Estonian: Pantsütopeenia, aneemia (3…4.
English: Adult patients with newly-diagnosed glioblastoma multiforme
Estonian: Esimest korda diagnoositud multiformse glioblastoomiga patsiendid:
English: NAME OF THE MEDICINAL PRODUCT Temomedac 5 mg hard capsules temozolomide
Estonian: Temomedac 5 mg kõvakapslid temosolomiid
English: NAME OF THE MEDICINAL PRODUCT Temomedac 140 mg hard capsules temozolomide
Estonian: Temomedac 140 mg kõvakapslid temosolomiid
English: NAME OF THE MEDICINAL PRODUCT Temomedac 100 mg hard capsules temozolomide
Estonian: Temomedac 100 mg kõvakapslid temosolomiid
English: Hyperglycaemia, weight decreased Weight decreased
Estonian: Hüperglükeemia, kehakaalu langus Kehakaalu langus
English: What Temomedac contains
Estonian: Temomedac on näidustatud:
English: Temomedac 5 mg hard capsules: gelatin, titanium dioxide (E 171), shellac, propylene glycol, indigo carmine (E 132) aluminium lake, yellow iron oxide (E 172) Temomedac 20 mg hard capsules: gelatine, titanium dioxide (E 171), shellac, propylene glycol, sunset yellow FCF aluminium Lake (E 110).
Estonian: Temomedac 5 mg kõvakapslid: želatiin, titaandioksiid (E 171), šellak, propüleenglükool, indigokarmiin Aluminium Lake (E 132), kollane raudoksiid (E 172).
English: Temomedac is used for the treatment of specific forms of brain tumours: - in adults with newly-diagnosed glioblastoma multiforme.
Estonian: Temomedaci kasutatakse teatud ajukasvajate raviks:
English: Temomedac 180 mg hard capsules: gelatin, titanium dioxide (E 171), shellac, propylene glycol, red iron oxide (E 172)
Estonian: Temomedac 180 mg kõvakapslid: želatiin, titaandioksiid (E 171), punane raudoksiid (E 172), šellak, propüleenglükool.
English: EU/1/09/605/008
Estonian: EU/1/09/605/007 EU/1/09/605/008
English: GT increased, AST increased
Estonian: ALAT-i aktiivsuse suurenemine
English: You should stop breast-feeding while receiving treatment with Temomedac.
Estonian: Temomedaci kasutamise ajal tuleb imetamine lõpetada.
English: EU/1/09/605/002
Estonian: EU/1/09/605/001 EU/1/09/605/002
English: The hard capsules (length approx. 22 mm) have a white body and cap with two stripes in blue ink on the cap and with “T 140 mg” in blue ink on the body.
Estonian: Kõvakapslitel (pikkus ligikaudu 22 mm) on läbipaistmatu valge põhiosa ja kaas, kaanel rohelise tindiga tehtud kaks triipu ning põhiosal sinise tindiga märgistus „T 140 mg”.
English: EU/1/09/605/004
Estonian: EU/1/09/605/003 EU/1/09/605/004
English: Very common (may affect more than 1 in 10 people): reduced number of blood cells (neutropenia or lymphopenia, thrombocytopenia), loss of appetite, headache, vomiting, nausea (feeling sick in your stomach), constipation (difficulty passing stools), tiredness.
Estonian: (neutropeenia või lümfopeenia, trombotsütopeenia), isu kaotus, peavalu, oksendamine, iiveldus (seedekulglaga seotud halb enesetunne), kõhukinnisus (raskendatud roojamine), väsimus.
English: EU/1/09/605/006
Estonian: EU/1/09/605/005 EU/1/09/605/006
English: Temomedac 180 mg hard capsules shellac, propylene glycol, red iron oxide (E172)
Estonian: Temomedac 180 mg kõvakapslid šellak propüleenglükool punane raudoksiid (E 172)
English: hyperbilirubinemia, cholestasis, hepatitis, hepatic injury, hepatic failure†
Estonian: Hüperbilirubineemia, sapipais, maksapõletik, maksakahjustus, maksapuudulikkus†
English: Temomedac 100 mg hard capsules shellac, propylene glycol, red iron oxide (E172), yellow iron oxide (E172), titanium dioxide (E171)
Estonian: Temomedac 100 mg kõvakapslid šellak propüleenglükool punane raudoksiid (E 172) kollane raudoksiid (E 172) titaandioksiid (E 171)
English: EU/1/09/605/010
Estonian: EU/1/09/605/009 EU/1/09/605/010
English: PHARMACEUTICAL FORM AND CONTENTS 5 hard capsules
Estonian: RAVIMVORM JA PAKENDI SUURUS
English: Summary of events reported with temozolomide in the post-marketing setting Uncommon:
Estonian: Kokkuvõte TMZ-i turuletulekujärgsel kasutamisel teatatud juhtudest Endokriinsüsteemi häired*
English: Further information on Binocrit can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Lisateave Binocriti kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Binocrit received a marketing authorisation valid throughout the EU on 28 August 2007.
Estonian: Binocrit on saanud müügiloa, mis kehtib kogu ELis, 28. augustil 2007.
English: What measures are being taken to ensure the safe and effective use of Binocrit?
Estonian: Mis meetmed võetakse, et tagada Binocriti ohutu ja efektiivne kasutamine?
English: This means that Binocrit is highly similar to another biological medicine (the ‘reference medicine') that is already authorised in the EU.
Estonian: See tähendab, et Binocrit on väga sarnane teise bioloogilise ravimiga (võrdlusravimiga), millel juba on ELis müügiluba.
English: The main measure of effectiveness was the change in the levels of haemoglobin between the start of the study and the evaluation period, between weeks 25 and 29.
Estonian: Efektiivsuse põhinäitaja oli uuringu algusest kuni hindamisperioodini (25.-29. nädalal) toimunud hemoglobiinisisalduse muutus.
English: The most common side effects with Binocrit (which may affect more than 1 in 10 people) are nausea (feeling sick),diarrhoea, vomiting, fever and headache.
Estonian: Binocriti kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on iiveldus, kõhulahtisus, oksendamine, palavik ja peavalu.
English: As for all medicines, data on the use of Binocrit are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Binocriti kasutamise kohta pidevat järelevalvet.
English: When Binocrit is used for autologous blood transfusion, the restrictions normally associated with this type of transfusion should be observed.
Estonian: Kui Binocriti kasutatakse autoloogsel vereülekandel, tuleb järgida seda tüüpi vereülekannete tavalisi piiranguid.
English: Binocrit (epoetin alfa)
Estonian: Binocrit (alfaepoetiin)
English: What is Binocrit and what is it used for?
Estonian: Mis on Binocrit ja milleks seda kasutatakse?
English: For more information about using Binocrit, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Binocriti kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: Side effects reported with Binocrit are carefully evaluated and any necessary action taken to protect patients.
Estonian: Binocriti kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: For patients with kidney failure, myelodysplastic syndromes or receiving chemotherapy, haemoglobin levels should remain within the recommended range (between 10 and 12 grams per decilitre in adults and between 9.5 and 11 g/dl in children).
Estonian: Neerupuudulikkuse, müelodüsplastiliste sündroomidega või keemiaravi saavatel patsientidel peab vere hemoglobiinisisaldus olema soovitatavas vahemikus (täiskasvanutel 10-12 g/dl ja lastel 9,5-11 g/dl).
English: The dose, the frequency of injection and how long it is used for also depend on why Binocrit is being used and on the patient's bodyweight, and are adjusted according to how well the medicine is working.
Estonian: Annus, süstimissagedus ja kasutamise kestus sõltuvad ka Binocriti kasutamise põhjusest ja patsiendi kehamassist ning neid kohandatakse vastavalt ravimi toimele.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Binocrit have been included in the summary of product characteristics and the package leaflet.
Estonian: Binocriti ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Binocrit is a medicine used for the following:
Estonian: Binocrit on ravim, mida kasutatakse järgmistel näidustustel:
English: Other information about Binocrit
Estonian: Muu teave Binocriti kohta
English: Binocrit is used when patients are at low or intermediate risk of developing acute myeloid leukaemia and have low levels of the natural hormone erythropoietin.
Estonian: Binocriti kasutatakse juhul, kui patsiendil on väike või keskmine risk ägeda müeloidleukeemia tekkeks ning tal on loodusliku hormooni, erütropoetiini vaegus.
English: What are the risks associated with Binocrit?
Estonian: Mis riskid Binocritiga kaasnevad?
English: The reference medicine for Binocrit is Eprex/Erypo.
Estonian: Binocriti võrdlusravim on Eprex/Erypo.
English: For the full list of side effects of Binocrit, see the package leaflet.
Estonian: Binocriti kõrvalnähtude täielik loetelu on pakendi infolehel.
English: All of the patients had been receiving Eprex/Erypo injected into a vein for at least 8 weeks before they were either switched to Binocrit or remained on Eprex/Erypo.
Estonian: Kõikidele patsientidele oli vähemalt 8 nädalat manustatud veenisüstidega Eprexit/Erypot, enne kui nad viidi üle ravile Binocritiga või jätkasid Eprexi/Erypo kasutamist.
English: The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Binocrit has a highly similar structure, purity and biological activity to Eprex/Erypo and is distributed in the body in the same way.
Estonian: Euroopa Ravimiamet otsustas, et vastavalt ELi nõuetele bioloogiliselt sarnaste ravimite kohta on tõendatud Binocriti struktuuri, puhtuse ja bioloogilise toime sarnasus Eprexi/Erypoga ning et Binocrit jaotub organismis samamoodi.
English: The active substance in Binocrit, epoetin alfa, is a copy of a hormone called erythropoietin, and works in exactly the same way as the natural hormone to stimulate the production of red blood cells in the bone marrow.
Estonian: Binocriti toimeaine alfaepoetiin on hormooni erütropoetiini koopia ja toimib täpselt samamoodi kui looduslik hormoon, stimuleerides luuüdis erütrotsüütide teket.
English: • to increase the amount of blood that can be taken in adult patients with moderate anaemia and normal blood iron levels who are going to have an operation and donate their own blood before surgery (autologous blood transfusion);
Estonian: • operatsioonieelselt võetava verekoguse suurendamiseks mõõduka aneemiaga ja vere normaalse rauasisaldusega täiskasvanud patsientidel, kellel on ees plaaniline operatsioon ning kellelt enne operatsiooni võetakse verd, et see hiljem neile üle kanda (autoloogne vereülekanne);
English: Binocrit contains the active substance epoetin alfa and is a ‘biosimilar medicine'.
Estonian: Binocrit sisaldab toimeainena alfaepoetiini ja on bioloogiliselt sarnane ravim.
English: Because Binocrit is a biosimilar medicine, the studies on effectiveness and safety of epoetin alfa carried out with Eprex/Erypo do not all need to be repeated for Binocrit.
Estonian: Et Binocrit on bioloogiliselt sarnane ravim, ei pea Eprexi/Erypoga tehtud alfaepoetiini efektiivsus- ja ohutusuuringuid Binocritiga kordama.
English: Binocrit, injected into a vein, was compared with the reference medicine in one main study involving 479 patients with anaemia caused by kidney problems.
Estonian: Veeni süstitavat Binocriti võrreldi võrdlusravimiga põhiuuringus, milles osales 479 neeruhäiretest põhjustatud aneemiaga patsienti.
English: Haemoglobin is the protein in red blood cells that carries oxygen around the body.
Estonian: Hemoglobiin on vere erütrotsüütide valk, mis kannab hapnikku organismis laiali.
English: Binocrit is available in pre-filled syringes of various strengths and is given as an injection into a vein or as an injection under the skin, depending on the condition for which the patient is being treated.
Estonian: Binocriti turustatakse eeltäidetud süstaldes (eri tugevustes) ning seda süstitakse veeni või subkutaanselt (naha alla), olenevalt ravitavast seisundist.
English: Therefore the Agency's view was that, as for Eprex/Erypo, the benefit of Binocrit outweighs the identified risk and it can be authorised.
Estonian: Seetõttu on amet arvamusel, et nagu ka Eprexi/Erypo korral, on Binocriti kasulikkus suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: How does Binocrit work?
Estonian: Kuidas Binocrit toimib?
English: An overview of Binocrit and why it is authorised in the EU
Estonian: Ülevaade ravimist Binocrit ja ELis müügiloa väljastamise põhjendus
English: • to reduce the need for blood transfusions in adults with moderate anaemia who are about to undergo major orthopaedic (bone) surgery, such as hip surgery.
Estonian: • vereülekannete vajaduse vähendamine mõõduka aneemiaga täiskasvanutel enne ulatuslikku ortopeedilist (luu-)operatsiooni, nt enne puusaoperatsiooni.
English: How is Binocrit used?
Estonian: Kuidas Binocriti kasutatakse?
English: Laboratory studies comparing Binocrit with the reference medicine Eprex/Erypo have shown that the active substance in Binocrit is highly similar to that in Eprex/Erypo in terms of structure, purity and biological activity.
Estonian: Binocriti võrreldi võrdlusravimiga Eprex/Erypo laboriuuringutes, mis tõendasid, et Binocriti toimeaine on struktuuri, puhtuse ja bioloogilise toime poolest väga sarnane Eprexi/Erypo toimeainega.
English: What benefits of Binocrit have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Binocriti kasulikkus?
English: A further study showed that Binocrit was safe and effective when given under the skin in 416 patients with chronic kidney failure.
Estonian: Täiendavas uuringus tõendati subkutaanselt süstitud Binocriti ohutus ja efektiivsus 416 kroonilise neerupuudulikkusega patsiendil.
English: Another study showed that Binocrit injected under the skin was as effective in maintaining haemoglobin levels as Eprex/Erypo in 114 cancer patients who were receiving chemotherapy.
Estonian: Veel ühes uuringus tõendati, et naha alla süstitud Binocrit oli 114 keemiaravi saanud vähipatsiendil hemoglobiinisisalduse säilitamisel sama efektiivne kui Eprex/Erypo.
English: Binocrit must not be used in the following groups:
Estonian: Ravimit ei tohi kasutada järgmistel patsiendirühmadel:
English: Patients switching to Binocrit maintained haemoglobin levels to the same extent as those continuing with Eprex/Erypo.
Estonian: Patsientidel, kes läksid üle ravile Binocritiga, säilis vere hemoglobiinisisaldus samal määral nagu Eprexi/Erypo kasutamist jätkanud patsientidel.
English: Studies have also shown that giving Binocrit produces similar levels of the active substance in the body to giving Eprex/Erypo.
Estonian: Samuti on uuringutes tõendatud, et Binocrit tekitab organismis toimeaine sarnase sisalduse kui Eprex/Erypo.